List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2715613/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	RYR1-Related Rhabdomyolysis: A Spectrum of Hypermetabolic States Due to Ryanodine Receptor Dysfunction. Current Pharmaceutical Design, 2022, 28, 2-14.	1.9	11
2	Prevalence of preoperative cognitive impairment in older surgical patients.: A systematic review and meta-analysis. Journal of Clinical Anesthesia, 2022, 76, 110574.	1.6	21
3	Fragmentation and roles of junctophilin1 in muscle of patients with cytosolic leak of stored calcium. Journal of General Physiology, 2022, 154, .	1.9	2
4	Development of a repeated-measures predictive model and clinical risk score for mortality in ventilated COVID-19 patients. Canadian Journal of Anaesthesia, 2022, 69, 343-352.	1.6	4
5	Mapping the current evidence on the anesthetic management of adult patients with neuromuscular disorders—a scoping review. Canadian Journal of Anaesthesia, 2022, , 1.	1.6	3
6	Referral Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing. Anesthesiology, 2022, 136, 940-953.	2.5	12
7	Effects of azumolene on arrhythmia substrate in a model of recurrent long-duration ventricular fibrillation. Biochemical and Biophysical Research Communications, 2022, 600, 123-129.	2.1	1
8	Pre-operative exercise and pyrexia as modifying factors in malignant hyperthermia (MH). Neuromuscular Disorders, 2022, 32, 628-634.	0.6	12
9	Variants in ASPH cause exertional heat illness and are associated with malignant hyperthermia susceptibility. Nature Communications, 2022, 13, .	12.8	7
10	Episodic RYR1-Related Crisis: Part of the Evolving Spectrum of RYR1-Related Myopathies and Malignant Hyperthermia-Like Illnesses. A&A Practice, 2021, 15, e01377.	0.4	2
11	Variant curation expert panel recommendations for RYR1 pathogenicity classifications in malignant hyperthermia susceptibility. Genetics in Medicine, 2021, 23, 1288-1295.	2.4	46
12	Effects of comprehensive geriatric care models on postoperative outcomes in geriatric surgical patients: a systematic review and meta-analysis. BMC Anesthesiology, 2021, 21, 127.	1.8	25
13	Untargeted metabolomics profiling of skeletal muscle samples from malignant hyperthermia susceptible patients. Canadian Journal of Anaesthesia, 2021, 68, 761-772.	1.6	9
14	The neuromuscular and multisystem features of RYR1-related malignant hyperthermia and rhabdomyolysis. Medicine (United States), 2021, 100, e26999.	1.0	8
15	Comment on "Overlapping Mechanisms of Exertional Heat Stroke and Malignant Hyperthermia: Evidence vs. Conjecture― Sports Medicine, 2021, , 1.	6.5	2
16	Screening for subjective cognitive decline in the elderly via subjective cognitive complaints and informant-reported questionnaires: a systematic review. BMC Anesthesiology, 2021, 21, 277.	1.8	12
17	The prevalence of unrecognized cognitive impairment in geriatric surgical patients: A systematic review and metaâ€analysis. Alzheimer's and Dementia, 2021, 17, .	0.8	0
18	Cardioprotective effects of dantrolene in doxorubicin-induced cardiomyopathy in mice. Heart Rhythm O2, 2021, 2, 733-741.	1.7	11

#	Article	IF	CITATIONS
19	Perioperative genetic screening: entering a new era. British Journal of Anaesthesia, 2020, 125, 859-862.	3.4	1
20	Adaptive thermogenesis enhances the life-threatening response to heat in mice with an Ryr1 mutation. Nature Communications, 2020, 11, 5099.	12.8	16
21	A multi-dimensional analysis of genotype–phenotype discordance in malignant hyperthermia susceptibility. British Journal of Anaesthesia, 2020, 125, 995-1001.	3.4	5
22	A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes. EClinicalMedicine, 2020, 25, 100464.	7.1	310
23	Anaesthesia and neuromuscular disorders: what a neurologist needs to know. Practical Neurology, 2020, , practneurol-2020-002633.	1.1	11
24	The case for routine screening for SARS-CoV-2 before surgery. Canadian Journal of Anaesthesia, 2020, 67, 1315-1320.	1.6	5
25	Intracellular calcium leak as a therapeutic target for RYR1-related myopathies. Acta Neuropathologica, 2020, 139, 1089-1104.	7.7	32
26	Intracellular calcium leak lowers glucose storage in human muscle, promoting hyperglycemia and diabetes. ELife, 2020, 9, .	6.0	20
27	Fatal awake malignant hyperthermia episodes in a family with malignant hyperthermia susceptibility: a case series. Canadian Journal of Anaesthesia, 2019, 66, 540-545.	1.6	16
28	An Assessment of Penetrance and Clinical Expression of Malignant Hyperthermia in Individuals Carrying Diagnostic Ryanodine Receptor 1 Gene Mutations. Anesthesiology, 2019, 131, 983-991.	2.5	31
29	Succinylcholine Use and Dantrolene Availability for Malignant Hyperthermia Treatment. Anesthesiology, 2019, 130, 41-54.	2.5	32
30	Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study. Canadian Journal of Anaesthesia, 2019, 66, 161-181.	1.6	10
31	Updated guide for the management of malignant hyperthermia. Canadian Journal of Anaesthesia, 2018, 65, 709-721.	1.6	54
32	Malignant Hyperthermia Susceptibility and Related Diseases. Anesthesiology, 2018, 128, 159-167.	2.5	91
33	Malignant Hyperthermia in the Post-Genomics Era. Anesthesiology, 2018, 128, 168-180.	2.5	120
34	Safety of Chronic Cardiac Ryanodine Receptor Modulation: AÂ10-Year Experience. JACC: Clinical Electrophysiology, 2018, 4, 1480-1481.	3.2	4
35	Round Table on Malignant Hyperthermia in Physically Active Populations: Meeting Proceedings. Journal of Athletic Training, 2017, 52, 377-383.	1.8	16
36	Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review. Canadian Journal of Anaesthesia, 2017, 64, 736-743.	1.6	31

#	Article	IF	CITATIONS
37	A Perioperative Smoking Cessation Intervention With Varenicline, Counseling, and Fax Referral to a Telephone Quitline Versus a Brief Intervention: A Randomized Controlled Trial. Anesthesia and Analgesia, 2017, 125, 571-579.	2.2	27
38	Skeletal Muscle Metabolic Dysfunction in Patients With Malignant Hyperthermia Susceptibility. Anesthesia and Analgesia, 2017, 125, 434-441.	2.2	11
39	A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia. Neurogenetics, 2016, 17, 245-249.	1.4	21
40	Cellular Pathophysiology of "MHHâ€; A Large Group of Patients with Equivocal Diagnosis of Malignant Hyperthermia. Biophysical Journal, 2016, 110, 98a.	0.5	0
41	Neuromuscular conditions associated with malignant hyperthermia in paediatric patients: A 25-year retrospective study. Neuromuscular Disorders, 2016, 26, 201-206.	0.6	24
42	An Expedited Care Pathway with Ambulatory Brachial Plexus Analgesia Is a Cost-effective Alternative to Standard Inpatient Care after Complex Arthroscopic Elbow Surgery. Anesthesiology, 2015, 123, 1256-1266.	2.5	9
43	Malignant Hyperthermia Testing in Probands without Adverse Anesthetic Reaction. Anesthesiology, 2015, 123, 548-556.	2.5	29
44	In Reply. Anesthesiology, 2015, 123, 732-733.	2.5	0
45	Accuracy of Malignant Hyperthermia Diagnoses in Hospital Discharge Records. Anesthesiology, 2015, 122, 55-63.	2.5	21
46	The couplonopathies: A comparative approach to a class of diseases of skeletal and cardiac muscle. Journal of General Physiology, 2015, 145, 459-474.	1.9	31
47	Exome analysis identifies <scp>B</scp> rody myopathy in a family diagnosed with malignant hyperthermia susceptibility. Molecular Genetics & Genomic Medicine, 2014, 2, 472-483.	1.2	20
48	From the Journal archives: Hereditary aspects of malignant hyperthermia. Canadian Journal of Anaesthesia, 2014, 61, 1122-1125.	1.6	1
49	Malignant Hyperthermia in Canada. Anesthesia and Analgesia, 2014, 118, 381-387.	2.2	120
50	Malignant hyperthermia testing in probands with NO adverse anesthetic reaction. BMC Anesthesiology, 2014, 14, .	1.8	0
51	Analysis of histomorphology in malignant hyperthermia-susceptible patients. Canadian Journal of Anaesthesia, 2013, 60, 982-989.	1.6	9
52	Novel excitation-contraction uncoupled RYR1 mutations in patients with central core disease. Neuromuscular Disorders, 2013, 23, 120-132.	0.6	24
53	<i>CASQ1</i> Gene Is an Unlikely Candidate for Malignant Hyperthermia Susceptibility in the North American Population. Anesthesiology, 2013, 118, 344-349.	2.5	29
54	Can Ultrasound of the Tibial Nerve Detect Diabetic Peripheral Neuropathy?. Diabetes Care, 2012, 35, 2575-2579.	8.6	92

#	Article	IF	CITATIONS
55	Incidence of Subclinical Neuropathy after Intraneural Injection. Anesthesiology, 2012, 116, 1152-1153.	2.5	1
56	Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population. Canadian Journal of Anaesthesia, 2011, 58, 504-513.	1.6	44
57	Ultrasound-Guided Nerve Blocks of the Upper Extremity. , 2011, , 227-237.		0
58	Ultrasound Provides a Reliable Test of Local Anesthetic Spread. Regional Anesthesia and Pain Medicine, 2010, 35, 361-363.	2.3	9
59	Confirmation of epidural catheter placement in a quadriplegic patient using a nerve stimulator. Canadian Journal of Anaesthesia, 2010, 57, 276-277.	1.6	4
60	A report of fulminant malignant hyperthermia in a patient with a novel mutation of the CACNA1S gene. Canadian Journal of Anaesthesia, 2010, 57, 689-693.	1.6	48
61	Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Canadian Journal of Anaesthesia, 2006, 53, 802-809.	1.6	54
62	Case report: Management of life-threatening oropharyngeal bleeding with recombinant factor VIIa. Canadian Journal of Anaesthesia, 2006, 53, 881-884.	1.6	4
63	Connection between Elastin Haploinsufficiency and Increased Cell Proliferation in Patients with Supravalvular Aortic Stenosis and Williams-Beuren Syndrome. American Journal of Human Genetics, 2002, 71, 30-44.	6.2	166